Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.21
-0.56 (-5.73%)
Aug 20, 2026, 4:00 PM EDT - Market closed
Vir Biotechnology Employees
Vir Biotechnology had 367 employees as of December 31, 2025. The number of employees decreased by 41 or -10.05% compared to the previous year.
Employees
367
Change (1Y)
-41
Growth (1Y)
-10.05%
Revenue / Employee
$826,232
Profits / Employee
-$685,774
Market Cap
1.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 367 | -41 | -10.05% |
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| Absci | 140 |
| Inhibrx Biosciences | 110 |
| Bicara Therapeutics | 103 |
| Tyra Biosciences | 87 |
| Avalyn Pharma | 55 |
VIR News
- 14 days ago - Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley - TheFly
- 14 days ago - Vir Biotechnology price target lowered to $19 from $21 at Leerink - TheFly
- 15 days ago - Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year - TheFly
- 15 days ago - Vir Biotechnology Earnings Call Transcript: Q2 2026 - Transcripts
- 15 days ago - Vir Biotechnology Slides: Q2 2026 - Filings
- 15 days ago - Vir Biotechnology Earnings release: Q2 2026 - Filings
- 15 days ago - Vir Biotechnology Quarterly report: Q2 2026 - Filings
- 15 days ago - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Business Wire